This site is intended for Healthcare professionals only.

Himalaya Drug Company eyes doubling sales to Rs 4,000 cr by FY20

Himalaya Drug Company eyes doubling sales to Rs 4,000 cr by FY20

New Delhi: Herbal wellness major Himalaya Drug Company is looking to double its sales turnover to Rs 4,000 crore in the next four years as it sharpens focus on wellness, babycare and personal care portfolio.

“We are looking at doubling our turnover to Rs 4,000 crore from Rs 2,000 crore at present in the next four years. We will register a CAGR of 20-25 per cent over the next four years. Our growth drivers will be wellness, baby care and personal care products,” its CEO Philipe Haydon told .

At present, Himalaya’s biggest vertical personal care contributes 42 per cent to its total sales, followed by pharmaceutical 34 per cent, baby care 13 per cent, animal health 4 per cent and wellness 4 per cent.

Elaborating on its wellness range, Haydon said: “Wellness portfolio is the fastest growing vertical in our company…we are looking at creating and defining wellness category in India. We will aggressively promote our wellness products as we truly believe it has the potential to revolutionise health management in India.”

Himalaya’s wellness range aims to address lifestyle- related health concerns such as joint pain, sleep disorder, acne and bowel disorder, arising out of an urban, fast paced life.

Under its wellness range, the company offers 28 tablets and 18 local applications medicines such as balms, therapeutic massage oils and creams.

“To spread awareness about about wellness products, we have created Himalaya wellness zones in pharmacy chains and supermarkets. At present, there are 2,000 Himalaya wellness zones across the country. In the next 10 days this number will double,” Haydon said.

The company is also looking at expanding its personal care range by introducing more shampoos, soaps, toothpaste and body lotions products, he added. SVK ABD MKJ ABM MR

Source: PTI
0 comment(s) on Himalaya Drug Company eyes doubling sales to Rs 4,000 cr by FY20

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted